Search Result

Results for "

α-Synuclein aggregation inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	α-synuclein (16) Amyloid-β (4) DYRK (2) Endogenous Metabolite (1)
By Research Areas:	Neurological Disease (25)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: α-synuclein

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-160116

α-Synuclein aggregate binder 1	α-synuclein	Neurological Disease
α-Synuclein aggregate binder 1 (Compound C05-05) is a collective binder and an inhibitor for α-synuclein aggregation. α-Synuclein aggregate binder 1 is utilized in Positron Emission Tomography (PET) imaging and fluorescence microscope, that can diagnose and ameliorate the neurodegenerative disease .

HY-157308

α-Synuclein inhibitor 10	α-synuclein	Neurological Disease
α-Synuclein inhibitor 10 (compound a8) inhibits the activity of α-Syn aggregation with low IC₅₀ value (1.08 μM). α-Synuclein inhibitor 10 exhibits good binding affinity to α-Syn residues. α-Synuclein inhibitor 10 can be used in the research of Parkinson's disease (PD) .

HY-163519

α-Synuclein inhibitor 13	α-synuclein	Neurological Disease
α-Synuclein inhibitor 13 is an inhibitor of α-synuclein (α-Syn). α-Synuclein inhibitor 13 inhibits the aggregation of α-Syn proteins and is able to break down formed fibers. It is mainly used in Parkinson's disease research .

HY-147644

α-Synuclein inhibitor 3	Others	Neurological Disease
α-Synuclein inhibitor 3 (Compound 7g) is a α-synuclein (α -Syn) aggregation inhibitor. α-Synuclein inhibitor 3 can be used for Parkinson’s disease research .

HY-152552

α-Synuclein inhibitor 8	α-synuclein	Neurological Disease
α-Synuclein inhibitor 8 is an active inhibitor of *α-Synuclein* with an IC₅₀ value of 2.5 µM. α-Synuclein inhibitor 8 has highly inhibition on the aggregation and disaggregation of α-Synuclein fibers. α-Synuclein inhibitor 8 reduces the formation of inclusions in neurons that can repairs damage neurons and improves Parkinson’s disease (PD)-like symptoms. α-Synuclein inhibitor 8 has high antioxidant activity and low cytotoxicity .

HY-149509

α-Synuclein inhibitor 9	α-synuclein	Neurological Disease
α-Synuclein inhibitor 9 (Compound 20C) is an *α-Synuclein* inhibitor. α-Synuclein inhibitor 9 binds to cavities in mature α-synuclein fibrils and reduces the β-sheet structure. α-Synuclein inhibitor 9 inhibits A53T α-Syn aggregation. α-Synuclein inhibitor 9 has neuroprotective effect, improves brain functional connection and relieves motor dysfunction.α-Synuclein inhibitor 9 can be used for Parkinson’s disease (PD) research. .

HY-157806

α-Synuclein inhibitor 12	α-synuclein	Neurological Disease
α-Synuclein inhibitor 12 (compound 4ce) is an inhibitor of α-Syn (α-synuclein) aggregation and can be used in the study of neurological diseases .

HY-P5082

α-Synuclein 4554W	α-synuclein	Neurological Disease
α-Synuclein 4554W is an inhibitor of *α-Synuclein* (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .

HY-147669

α-Synuclein inhibitor 7	Others	Neurological Disease
α-Synuclein inhibitor 7 (compound 3gf) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC₅₀ of 1.95 μM and inhibition ratio at 30 μM of 85.8% .

HY-147666

α-Synuclein inhibitor 4	Others	Neurological Disease
α-Synuclein inhibitor 4 (compound 3gh) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC₅₀ of 0.98 μM and inhibition ratio at 30 μM of 91.2% .

HY-147667

α-Synuclein inhibitor 5	α-synuclein	Neurological Disease
α-Synuclein inhibitor 5 (compound 4aa) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC₅₀ of 1.22 μM and inhibition ratio at 30 μM of 94.3% .

HY-147668

α-Synuclein inhibitor 6	Others	Neurological Disease
α-Synuclein inhibitor 6 (compound 3ge) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC₅₀ of 1.70 μM and inhibition ratio at 30 μM of 94.4% .

HY-144696

Dyrk1A/α-synuclein-IN-2	DYRK	Neurological Disease
Dyrk1A/α-synuclein-IN-2 (Compound b20) is a dual Dyrk1A and **α-synuclein aggregation** inhibitor with an IC₅₀ of 7.8 µM for α-synuclein. Dyrk1A/α-synuclein-IN-2 has high predictive CNS penetration and neuroprotective effect .

HY-130398

Aerophobin-2	α-synuclein	Neurological Disease
Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of *α-synuclein* (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy .

HY-120475

PBT434 ATH434	α-synuclein	Neurological Disease
PBT434 is a potent, orally active and cross the blood-brain barrier **α-synuclein aggregation** inhibitor. PBT434 can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 has the potential for the research of Parkinson’s disease (PD) .

HY-144695

Dyrk1A/α-synuclein-IN-1	DYRK	Neurological Disease
Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual Dyrk1A and **α-synuclein aggregation** inhibitor with IC₅₀ values of 177 nM and 10.5 µM, respectively. Dyrk1A/α-synuclein-IN-1 has high predictive CNS penetration and neuroprotective effect .

HY-120475A

PBT434 mesylate ATH434 mesylate	α-synuclein	Neurological Disease
PBT434 methanesulfonate is a potent, orally active and cross the blood-brain barrier **α-synuclein aggregation** inhibitor. PBT434 methanesulfonate can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 methanesulfonate inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 methanesulfonate prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 methanesulfonate has the potential for the research of Parkinson’s disease (PD) .

HY-124876

SynuClean-D SC-D	α-synuclein	Neurological Disease
SynuClean-D (SC-D) is an inhibitor of *α-synuclein* aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease .

HY-153416

QR-0217	Amyloid-β	Neurological Disease
QR-0217 is a potent Aβ1-40 aggregation inhibitor with an IC₅₀ value of 7.5 µM. QR-0217 inhibits α-synuclein aggregation. QR-0217 reduces memory impairments caused by Aβ neurotoxicity .

HY-163739

LETC	α-synuclein	Neurological Disease
LETC is an orally active **α-synuclein (α-Syn) aggregation** inhibitor with an EC₅₀ of 66 nM in transfected DH60.21 neuroblastoma cells. LETC can cross the blood-brain barrier. LETC can be used for the study of synucleinopathies .

HY-170553

ZPD-2	α-synuclein	Neurological Disease
ZPD-2 inhibits the aggregation of C-terminally truncated and full-length α-synuclein. ZPD-2 inhibits the formation and fibrillation of α-Syn, thereby preventing its propagation. ZPD-2 can be used in research of Parkinson's disease .

HY-W010041

Scyllo-Inositol	Amyloid-β Endogenous Metabolite	Neurological Disease
Scyllo-Inositol, an amyloid inhibitor, potentialy inhibits α-synuclein aggregation. Scyllo-Inositol stabilizes a non-fibrillar non-toxic form of amyloid-β peptide (Aβ42) in vitro, reverses cognitive deficits, and reduces synaptic toxicity and lowers amyloid plaques in an Alzheimer's disease mouse model .

HY-101855

Emrusolmin Anle138b	Amyloid-β	Neurological Disease
Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .

HY-159945

tau Protein/α-synuclein-IN-2	Amyloid-β α-synuclein	Neurological Disease
Tau Protein/α-synuclein-IN-2 (Compound 14T) is a blood-brain barrier penetrating tau and α-syn inhibitor. Through its thiourea linker structure, Tau Protein/α-synuclein-IN-2 dose-dependently reduces α-syn oligomerization. In biosensor cells, Tau Protein/α-synuclein-IN-2 prevents the seeding effect of tau aggregation. In the M17D neuroblastoma model, Tau Protein/α-synuclein-IN-2 exhibits anti-inclusion effects. Additionally, Tau Protein/α-synuclein-IN-2 reduces Aβ plaque formation. Tau Protein/α-synuclein-IN-2 holds promise for Alzheimer's disease and Parkinson's disease research.

HY-125287

(Rac)-Minzasolmin (Rac)-UCB0599; NPT200-11	α-synuclein	Neurological Disease
(Rac)-Minzasolmin ((Rac)-UCB0599) is a brain penetrating inhibitor of accumulation of *alpha-synuclein* (ASYN) misfolding and aggregation. (Rac)-Minzasolmin can be used for research of Parkinson's disease .

Cat. No.	Product Name	Target	Research Area

HY-P5082

α-Synuclein 4554W	α-synuclein	Neurological Disease
α-Synuclein 4554W is an inhibitor of *α-Synuclein* (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .

Scyllo-Inositol	Structural Classification Natural Products Source classification Endogenous metabolite	Amyloid-β Endogenous Metabolite
Scyllo-Inositol, an amyloid inhibitor, potentialy inhibits α-synuclein aggregation. Scyllo-Inositol stabilizes a non-fibrillar non-toxic form of amyloid-β peptide (Aβ42) in vitro, reverses cognitive deficits, and reduces synaptic toxicity and lowers amyloid plaques in an Alzheimer's disease mouse model .

Aerophobin-2	Structural Classification Natural Products Marine natural products Source classification Sponge	α-synuclein
Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of *α-synuclein* (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

α-Synuclein aggregation inhibitor

Inhibitors & Agonists

Peptides

NaturalProducts

Natural
Products